SCHEMBL6475134

SCHEMBL6475134

Cc1ccc(CCc2ccc(Nc3cccc(C(=O)O)c3)cc2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.53
ADRB3 P13945 2/20 0.53
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
AKR1C3 P42330 3/20 0.49
AKR1C2 P52895 3/20 0.49
MAPT P10636 5/20 0.47
ALDH1A1 P00352 5/20 0.47
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
AGTR1 P30556 1/20 0.47
CBS P35520 1/20 0.46
RHOA P61586 1/20 0.46
MAPK1 P28482 3/20 0.46
RAB9A P51151 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475359 0.89 MEN1 (0.49) ADRB1ADRB3MEN1KMT2ATDP1
SCHEMBL6474710 0.89 MEN1 (0.62) ADRB1ADRB3MEN1KMT2ATDP1
SCHEMBL27581471 0.83 ADRB1 (0.51) ADRB1ADRB3MEN1KMT2ATDP1
SCHEMBL6475192 0.78 MEN1 (0.80) MEN1KMT2ATDP1RECQLBLM
SCHEMBL4106539 0.77 CBS (0.76) MEN1KMT2AMAPTSMN1; SMN2CBS
SCHEMBL6480568 0.77 MEN1 (0.62) ADRB1ADRB3MEN1KMT2ATDP1
SCHEMBL6481933 0.76 MEN1 (0.65) ADRB1ADRB3MEN1KMT2ATDP1
SCHEMBL13280280 0.75 AKR1C3 (0.65) ADRB1ADRB3MEN1KMT2AAKR1C3
SCHEMBL13280136 0.75 AKR1C3 (0.65) MEN1KMT2AAKR1C3AKR1C2MAPT
SCHEMBL6482802 0.74 MEN1 (0.65) MEN1KMT2ATDP1RECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 ADRB1 577/4885ADRB3 1603/4885MEN1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.